In addition, it has been reported that targeting BAFF with a monoclonal antibody (belimumab) in patients with systemic lupus erythematosus (SLE) results in the inhibition of B cell activation, proliferation, and differentiation, which in turn reduces the role of these cells in disease activity [26]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.